Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Completed · Phase 2
Conditions studied: Obsessive-Compulsive Disorder (OCD)
In brief
This research study tests whether GLYX-13 - an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor.
Key facts
- Study ID
- NCT02267629
- Run by
- New York State Psychiatric Institute
- People needed
- 7
- Starts
- 2014-10-01
- Expected to finish
- 2016-02-01
- Last updated by the study team
- 2017-07-18
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- New York State Psychiatric Insitute — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.